Date Published: May 25, 2010
Publisher: Public Library of Science
Author(s): Stefan Ambs
Abstract: Stefan Ambs provides a perspective on a recent research article by Paul Pharoah and colleagues that evaluated the prognostic significance of immunohistochemical subtype classification in early breast cancer.
Partial Text: Advances in hormone therapy and combination chemotherapy have led to significant declines in disease recurrence and mortality due to breast cancer ,. However, the burden of developing a deadly disease remains unequal. A disease diagnosis at age 50 or younger is still more likely to have a fatal outcome than the same diagnosis at an older age. Moreover, African-American women and women diagnosed with estrogen, progesterone, and HER2 receptor–negative disease (termed triple-negative breast cancer) continue to experience an excessive mortality and have not benefited from the advances in breast cancer therapy as much as other patient groups ,. Currently, about 10% of breast cancer patients will succumb to the disease within the first 5 years following the initial diagnosis , despite many being diagnosed with an early-stage disease. The relative risk of dying from breast cancer has a peak between 2 and 4 years post-diagnosis , and we can only speculate why so many women die in that period. It remains a great challenge to prospectively identify those breast cancer patients who have been diagnosed with a primary disease but have a low chance of surviving when treated with current standard therapy.
Landmark studies by Perou et al. and by Sorlie et al. identified five distinct subtypes, which are different from one another in their gene expression characteristics ,. They include two estrogen receptor (ER)-positive subtypes, termed luminal A and B, and three ER-negative subtypes, termed basal-like, HER2-positive, and normal breast-like tumors. Luminal tumors develop more frequently than the other subtypes and share many features with luminal epithelial cells lining the mammary ducts, but tumors in the luminal B subgroup also aberrantly overexpress the HER2 receptor or proliferation marker genes that distinguish them from the HER2-negative luminal A tumors. Basal-like breast cancer has similarities with normal breast basal epithelial cells and is commonly identified by a lack of ER and HER2 receptor expression and by the expression of either cytokeratin 5/6 or epidermal growth factor receptor (EGFR). This group of tumors is characterized by a high proliferation rate, pushing border of invasion, and the frequent expression of cancer stem cell markers . Basal-like breast tumors share many features with triple-negative tumors although the overlap is not complete, raising the question of whether they should be treated as two different entities in clinical practice. A diagnosis of either the basal-like or triple negative disease signals a diminished chance of survival because of high relapse rates within the first three years after diagnosis, mainly affecting patients with residual disease despite the use of adjuvant chemotherapy.
Numerous studies have shown that immunohistochemistry for hormone and EGFR receptors and cytokeratin 5/6 expression is a simple and workable way to determine the intrinsic subtype of breast tumors for clinical applications ,. Moreover, immunohistochemical classification into either a luminal A, HER2-expressing, basal-like, or triple-negative tumors was found to be associated with a patient’s survival, and tumor subtypes were shown to respond differently to adjuvant therapy, with many basal-like and HER2-positive tumors being particularly sensitive to anthracycline-based combination therapy ,. These findings suggested that immunohistochemistry-based classification of breast tumors may improve prognostication and a patient’s assignment to therapy beyond current standards in breast cancer care. However, several studies challenged this paradigm and signs emerged that categorization of breast tumors into good and poor outcome groups based on their intrinsic subtype classification may have limitations. Currently unknown factors seem to further separate several of the intrinsic subtypes into two clinically distinct subgroups: one with patients who succumb to the disease early and one with patients who continue to survive the disease .
Pharoah and colleagues describe a pattern for short- and long-term breast cancer survival that reflects a constant mortality rate for ER-positive, HER2-negative tumors and a bimodal mortality rate pattern for all other breast cancer subtypes, with an initially high mortality rate that progressively declines. Changes in mortality rates and disease prognosis with increasing survival time will complicate decision making in clinical practice. What causes mortality rates to change when patients survived the first years after diagnosis? It is partly explained by the excess risk of early relapse, leading to excess mortality within the first five years, for patients that have residual disease and have been diagnosed with a basal-like, triple-negative, or HER2-positive tumor. It appears that these relapsing patients cannot be saved by current standard therapy. It is a limitation of the immunohistochemistry approach applied by Pharoah and colleagues, and of the intrinsic breast cancer subtype model in general, that it cannot differentiate within a subtype between those patients who will succumb to the disease within a few years and those who will continue to survive the disease. It is unlikely that other prediction models will do much better. Several gene expression signatures developed for prognostication showed high rates of concordance with the intrinsic subtype model in their outcome prediction, and assigned similar recurrence scores to individual tumors .
Two key areas of uncertainty exist in the management of breast cancer. The first deals with the problem of identifying patients who are the most appropriate candidates for receiving adjuvant therapy. Adjuvant systemic therapy significantly improves survival of breast cancer patients. However, many patients with early-stage disease may not need adjuvant systemic therapy. Gene signature–derived tumor markers can assist in selecting those patients who will benefit most from adjuvant therapy . Thus, immunohistochemistry-based subtype classification holds the promise that it can be used clinically in directing patients to the most appropriate therapy choice. The other key area is to identify those patients who are at a high risk of disease recurrence and mortality, and who will not respond to current standard therapy. Subtype classification may not be very useful in identifying those patients. Currently, we do not know whether increased metastatic potential, intrinsic drug resistance, or a combination of both is the culprit that makes a subset of primary tumors so deadly. Basal-like tumors tend to develop visceral metastases more commonly than other tumor subtypes, and it has been hypothesized that these tumors have a distinct molecular mechanism of metastatic spread that may evade detection . Moreover, these tumors and triple-negative tumors may share molecular defects in their DNA repair capacity, which makes them sensitive to certain classes of DNA-damaging therapeutics. This hypothesis should be explored. Lastly, we need additional research to develop markers that can differentiate between those patients who will relapse early and those who will survive. Some studies have begun to characterize tumors from relapsing patients . If successful, a molecular profile should emerge that will aid in the development of more targeted therapies that can eradicate these tumors.